Life Technologies Corporation company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

lifetechnologies.com

Founded Year

2008

Stage

Acq - P2P | Acquired

Valuation

$0000 

About Life Technologies Corporation

Life Technologies Corporation is a global biotechnology company that provides products and services to customers in the fields of scientific research, genetic analysis and applied sciences. With a presence in more than 180 countries, the company's portfolio of 50,000 end-to-end solutions is secured by more than 5,000 patents and licenses that span the entire biological spectrum – scientific exploration, molecular diagnostics, 21st century forensics, regenerative medicine and agricultural research.

Life Technologies Corporation Headquarter Location

5791 Van Allen Way

Carlsbad, California, 92008,

United States

760-603-7200

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Life Technologies Corporation

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Life Technologies Corporation is included in 4 Expert Collections, including Synthetic Biology.

S

Synthetic Biology

382 items

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

M

Medical Devices

295 items

Companies that received PMA from the FDA since 2014. Companies tagged as #FDAPMA

H

Health Monitoring & Diagnostics

76 items

Companies developing companion diagnostics and technology enabling the development of companion diagnostics. Tagged as #CompanionDx

Life Technologies Corporation Patents

Life Technologies Corporation has filed 2070 patents.

The 3 most popular patent topics include:

  • Molecular biology
  • Biotechnology
  • DNA
patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/30/2020

5/24/2022

Microscopy, Broadcast engineering, Microscopes, Video formats, Image processing

Grant

Application Date

9/30/2020

Grant Date

5/24/2022

Title

Related Topics

Microscopy, Broadcast engineering, Microscopes, Video formats, Image processing

Status

Grant

Latest Life Technologies Corporation News

Hannah Life Technologies Raises a $5.15M Pre-Series A to Take Its At-Home Fertility Solution to Market

May 13, 2022

Fertility startup Hannah Life Technologies has raised $5.15 million in pre-Series A funding led by Monk’s Hill Ventures. Other participants in the round include Golden Gate Ventures, Anthro Ventures and medical technology entrepreneur Dr. Jack Wang. The company was co-founded in 2019 by Benjamin Tee and Prusothman Raja, is based in Singapore and participated in Y Combinator’s S20 cohort. in an interview…

  • When was Life Technologies Corporation founded?

    Life Technologies Corporation was founded in 2008.

  • Where is Life Technologies Corporation's headquarters?

    Life Technologies Corporation's headquarters is located at 5791 Van Allen Way, Carlsbad.

  • What is Life Technologies Corporation's latest funding round?

    Life Technologies Corporation's latest funding round is Acq - P2P.

  • Who are the investors of Life Technologies Corporation?

    Investors of Life Technologies Corporation include Thermo Fisher Scientific.

  • Who are Life Technologies Corporation's competitors?

    Competitors of Life Technologies Corporation include Sirion Biotech, KIYATEC, HTG Molecular Diagnostics, Mersana Therapeutics, WaferGen Bio-systems, ZyGEM, Pieris, Roka Bioscience, Entelos, EnCoate and 20 more.

You May Also Like

Solidus Biosciences Logo
Solidus Biosciences

Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products. The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.

Van Andel Institute Logo
Van Andel Institute

VARi has several research programs in basic sciences that will improve our understanding of the cancer process, including programs rich in functional genomics. They have a long-term commitment to the development of programs that facilitate the translation of these basic science discoveries into therapeutic strategies for attacking cancer and thus improving human health.

E
EMTech

EMTech, a spin-off of BiOva, LLC, is researching, developing, and manufacturing technologies for the metabolic enhancement of the enzymes and bacteria used in the fermentation industry. The company's current products and ongoing research projects show applications that enhance productivity in the ethanol, pharmaceutical, beer, wine, and dairy industries.

A
Axela Biosensors

Axela is delivering on its mission to provide a simple and effective approach to personalized medicine by exploiting the dotLab System in research markets today to generate tomorrow's diagnostics. This strategy of offering a common technology platform to both markets aims to provide a opportunity to capitalize on discoveries. The approach has already resulted in applications with the potential to address segments of the large, underserved markets of oncology and cardiology that will be the focus of two funded clinical trials this summer and growing installed customer base. For a time these leading clinical researchers can use the direct understanding of protein interactions to develop quantitative assays on a single platform. dot technology has shortened the transition from protein discovery to application. The ability to measure biomolecular complexes in real-time aims to provide for new approaches to disease management.

KIYATEC Logo
KIYATEC

KIYATEC specializes in modeling and predicting cancer patient response to drug therapies, using ex vivo 3D cell culture technology, in order to inform clinical decision making and drive drug development. Its predictive clinical tests provide oncologists with patient-specific response profiles to current standard of care drugs prior to treatment selection.

N
Nanosep

Nanosep is a company with a new high performing environmentally friendly analytical technology to be used in the pharmaceutical and biotech industry. With the Nanosep technology, a customer can easily get results from complicated samples, such as blood plasma and pharmaceutical products. Both faster, with less effort and with higher precision compared to technologies available on the market today

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.